Will Safety Issues Derail Denosumab? FDA Sets Advisory Cmte. Slot
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen’s much-ballyhooed monoclonal antibody, now called Prolia, faces safety questions at the Aug. 13 Advisory Committee for Reproductive Health Drugs meeting.
You may also be interested in...
GSK Denosumab Deal Gives Amgen A Leg Up In Primary Care
Thanks to a new deal with GlaxoSmithKline for the marketing of its cherished bone drug denosumab outside the U.S. in post-menopausal osteoporosis, Amgen gets a much needed, solid launch pad for its first major venture into primary care
GSK Denosumab Deal Gives Amgen A Leg Up In Primary Care
Thanks to a new deal with GlaxoSmithKline for the marketing of its cherished bone drug denosumab outside the U.S. in post-menopausal osteoporosis, Amgen gets a much needed, solid launch pad for its first major venture into primary care
Amgen, GSK To Team Up On Denosumab Commercialization in Europe
Amgen's big bet on denosumab gets a boost from a Big Pharma partner in Europe, with U.S. rights intact.